Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was introduced for the first time in Italy. However, the im...

Descripción completa

Detalles Bibliográficos

Autores principales:	Melodie O. Aricò, Francesco Accomando, Daniela Trotta, Giulia Marozzi, Anthea Mariani, Claudia Rossini, Claudio Cafagno, Letizia Lorusso, Martina Fornaro, Enrico Valletta, Désirée Caselli, Maurizio Aricò
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2025-09-01
Colección:	Infectious Disease Reports
Materias:	bronchiolitis respiratory syncytial virus nirsevimab health disparities
Acceso en línea:	https://www.mdpi.com/2036-7449/17/5/115
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!